These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34625366)

  • 1. Transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome - chronic kidney disease: Impact on renal function.
    Ponzo P; Campion D; Rizzo M; Roma M; Caviglia GP; Giovo I; Rizzi F; Bonetto S; Saracco GM; Alessandria C
    Dig Liver Dis; 2022 Aug; 54(8):1101-1108. PubMed ID: 34625366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
    Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
    Wong F; Pantea L; Sniderman K
    Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications.
    Will V; Rodrigues SG; Stirnimann G; Gottardi A; Bosch J; Berzigotti A
    United European Gastroenterol J; 2020 Oct; 8(8):961-969. PubMed ID: 32588789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems.
    Guevara M; Ginès P; Bandi JC; Gilabert R; Sort P; Jiménez W; Garcia-Pagan JC; Bosch J; Arroyo V; Rodés J
    Hepatology; 1998 Aug; 28(2):416-22. PubMed ID: 9696006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver-HERO: hepatorenal syndrome-acute kidney injury (HRS-AKI) treatment with transjugular intrahepatic portosystemic shunt in patients with cirrhosis-a randomized controlled trial.
    Ripoll C; Platzer S; Franken P; Aschenbach R; Wienke A; Schuhmacher U; Teichgräber U; Stallmach A; Steighardt J; Zipprich A;
    Trials; 2023 Apr; 24(1):258. PubMed ID: 37020315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in patients with refractory ascites treated by transjugular intrahepatic porto-systemic shunt: From the liver to the kidney.
    Hamel B; Guillaud O; Roman S; Vallin M; Pilleul F; Valette PJ; Henry L; Guibal A; Mion F; Dumortier J
    Dig Liver Dis; 2014 Nov; 46(11):1001-7. PubMed ID: 25096966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites.
    Deschênes M; Dufresne MP; Bui B; Fenyves D; Spahr L; Roy L; Lafortune M; Pomier-Layrargues G
    Am J Gastroenterol; 1999 May; 94(5):1361-5. PubMed ID: 10235219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update.
    Rössle M; Gerbes AL
    Gut; 2010 Jul; 59(7):988-1000. PubMed ID: 20581246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transjugular intrahepatic portosystemic shunt for cirrhosis and ascites: Effects in patients with organic or functional renal failure.
    Michl P; Gülberg V; Bilzer M; Waggershauser T; Reiser M; Gerbes AL
    Scand J Gastroenterol; 2000 Jun; 35(6):654-8. PubMed ID: 10912668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transjugular Intrahepatic Porto-Systemic Shunt in Patients with Liver Cirrhosis and Model for End-Stage Liver Disease ≥15.
    Ascha M; Hanouneh M; S Ascha M; Zein NN; Sands M; Lopez R; Hanouneh IA
    Dig Dis Sci; 2017 Feb; 62(2):534-542. PubMed ID: 27154510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis.
    Bai M; Qi XS; Yang ZP; Yang M; Fan DM; Han GH
    World J Gastroenterol; 2014 Mar; 20(10):2704-14. PubMed ID: 24627607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does advanced chronic kidney disease impact transjugular intrahepatic portosystemic shunt efficacy and safety?
    Lakhoo J; Gunasekaran SS; Lokken RP; Lipnik AJ; Ray CE; Bui JT; Gaba RC
    Acta Gastroenterol Belg; 2017; 80(2):243-248. PubMed ID: 29560689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study.
    Brensing KA; Textor J; Perz J; Schiedermaier P; Raab P; Strunk H; Klehr HU; Kramer HJ; Spengler U; Schild H; Sauerbruch T
    Gut; 2000 Aug; 47(2):288-95. PubMed ID: 10896924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The natural history and management of hepatorenal disorders: from pre-ascites to hepatorenal syndrome.
    Blendis L; Wong F
    Clin Med (Lond); 2003; 3(2):154-9. PubMed ID: 12737373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial.
    Narahara Y; Kanazawa H; Fukuda T; Matsushita Y; Harimoto H; Kidokoro H; Katakura T; Atsukawa M; Taki Y; Kimura Y; Nakatsuka K; Sakamoto C
    J Gastroenterol; 2011 Jan; 46(1):78-85. PubMed ID: 20632194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of refractory ascites and hepatorenal syndrome.
    Chutaputti A
    J Gastroenterol Hepatol; 2002 Apr; 17(4):456-61. PubMed ID: 11982727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute kidney injury and hepatorenal syndrome in cirrhosis.
    Egerod Israelsen M; Gluud LL; Krag A
    J Gastroenterol Hepatol; 2015 Feb; 30(2):236-43. PubMed ID: 25160511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatorenal syndrome.
    Bataller R; Ginès P; Arroyo V; Rodés J
    Clin Liver Dis; 2000 May; 4(2):487-507. PubMed ID: 11232202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis.
    Dissegna D; Sponza M; Falleti E; Fabris C; Vit A; Angeli P; Piano S; Cussigh A; Cmet S; Toniutto P
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):626-632. PubMed ID: 30550458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.